WO2023016551A1 - Pyrrolo six-membered heteroaromatic compound for treating or preventing graft-versus-host disease - Google Patents
Pyrrolo six-membered heteroaromatic compound for treating or preventing graft-versus-host disease Download PDFInfo
- Publication number
- WO2023016551A1 WO2023016551A1 PCT/CN2022/112101 CN2022112101W WO2023016551A1 WO 2023016551 A1 WO2023016551 A1 WO 2023016551A1 CN 2022112101 W CN2022112101 W CN 2022112101W WO 2023016551 A1 WO2023016551 A1 WO 2023016551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- versus
- host disease
- graft
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims abstract description 60
- 208000024908 graft versus host disease Diseases 0.000 title claims abstract description 60
- 150000002390 heteroarenes Chemical class 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 40
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 239000003246 corticosteroid Substances 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 16
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 15
- 229960004618 prednisone Drugs 0.000 claims description 14
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 229960001810 meprednisone Drugs 0.000 claims description 7
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 7
- 229960001334 corticosteroids Drugs 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 5
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000004083 survival effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960000215 ruxolitinib Drugs 0.000 description 5
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000024340 acute graft versus host disease Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011291 current first-line treatment Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- -1 heteroaryl compound Chemical class 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940096335 prednisone 1 mg Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present disclosure relates to a pyrrolo six-membered heteroaryl compound for treating or preventing anti-host disease.
- GVHD graft-versus-host disease
- aGVHD acute graft-versus-host disease
- cGVHD chronic graft-versus-host disease
- corticosteroids have become the first-line regimen for the treatment of cGvHD, ie, prednisone (starting dose 1 mg/kg/d) or equivalent doses of methylprednisolone for systemic immunosuppressive therapy.
- the drugs used for the second-line treatment of cGVHD include: mTOR inhibitors, mycophenolate mofetil, rituximab, alemtuzumab, thalidomide, imatinib, spray Sistatin and methotrexate, etc. These drugs can relieve some patients, but due to the strong immunosuppression of the drugs, the incidence of fungal, viral, bacterial and other infections increases significantly; and long-term use of glucocorticoids can lead to diabetes, Osteoporosis, negative nitrogen balance, malnutrition.
- JAK inhibitors play an important role in the inflammatory response and tissue damage of GVHD.
- JAK inhibitors can block the JAK-STAT molecular pathway and reduce the level of inflammatory cytokines, even in patients with negative JAK mutations.
- Ruxolitinib, Baricitinib, etc. have some clinical experience in some GVHD patients, among which Ruxolitinib is approved for the treatment of steroid-refractory acute GVHD in adults and children aged 12 and over.
- (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine -4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide is a class of JAK kinase inhibitor compounds with in vivo and in vitro activity and high absorption
- the disclosure provides the use of the compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing graft-versus-host disease,
- the graft versus host disease is chronic graft versus host disease. According to the 2014 NIH chronic graft-versus-host disease diagnosis and curative effect grading standards, it is graded, including mild graft-versus-host disease, moderate graft-versus-host disease and severe graft-versus-host disease. In some embodiments, the graft versus host disease is moderate graft versus host disease. In some embodiments, the graft-versus-host disease is more than moderate graft-versus-host disease. In some embodiments, the graft versus host disease is moderate-severe graft versus host disease. In some embodiments, the graft versus host disease is severe graft versus host disease.
- a patient with graft-versus-host disease in the present disclosure is one who has undergone cell transplantation.
- the patient with graft versus host disease has undergone allogeneic bone marrow or hematopoietic stem cell transplantation.
- administration is based on the patient's body weight, and the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 0.1-10.0 mg/kg, specifically 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4mg/kg, 0.5mg/kg, 0.6mg/kg, 0.7mg/kg, 0.8mg/kg, 0.9mg/kg, 1.0mg/kg, 1.2mg/kg, 1.4mg/kg, 1.6 mg/kg, 1.8mg/kg, 2.0mg/kg, 2.2mg/kg, 2.4mg/kg, 2.6mg/kg, 2.8mg/kg, 3.0mg/kg, 3.2mg/kg, 3.4mg/kg, 3.6 mg/kg, 3.8mg/kg, 4.0mg/kg, 4.2mg/kg, 4.4mg/kg, 4.6mg/kg, 4.8mg/kg, 5.0mg/kg, 5.2mg/kg,
- the dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 0.1-5.0 mg/kg. In other embodiments, the dose of the compound of formula I or its pharmaceutically acceptable salt in mammals is 1.0-5.0 mg/kg. In other embodiments, the dose of the compound of formula I or its pharmaceutically acceptable salt in mammals is 4.0-6.0 mg/kg. In other embodiments, the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 5.0-6.0 mg/kg.
- the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 1-50 mg, specifically 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2.0 mg, 2.2 mg , 2.4mg, 2.6mg, 2.8mg, 3.0mg, 3.2mg, 3.4mg, 3.6mg, 3.8mg, 4.0mg, 4.2mg, 4.4mg, 4.6mg, 4.8mg, 5.0mg, 5.2mg, 5.4mg, 5.6 mg, 5.8mg, 6.0mg, 6.2mg, 6.4mg, 6.6mg, 6.8mg, 7.0mg, 7.2mg, 7.4mg, 7.6mg, 7.8mg, 8.0mg, 8.2mg, 8.4mg, 8.6mg, 8.8mg, 9.0mg, 9.2mg, 9.4mg, 9.6mg, 9.8mg, 10.0mg, 15mg, 20m
- the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-10 mg. In certain embodiments, the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-5 mg. In certain embodiments, the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 4-8 mg.
- the compound of formula I, or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition in the form of a 2 mg dosage.
- the compound of Formula I, or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition in the form of a 4 mg dosage.
- the compound of Formula I, or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition in an 8 mg dosage form.
- the additional therapeutic agent is a corticosteroid (including but not limited to prednisone, methylprednisone, hydrocortisone, dexamethasone, betamethasone, or beclomethasone dipropionate). In certain embodiments, the additional therapeutic agent is prednisone or methylprednisone.
- the additional therapeutic agent such as a corticosteroid
- the additional therapeutic agent is administered in a mammalian human at a dose of 0.1-10.0 mg/kg.
- the additional therapeutic agent, such as a corticosteroid is administered in a mammalian human at a dose of 1.0-2.0 mg/kg.
- the additional therapeutic agent, such as a corticosteroid is administered in a mammalian human at a dose of 0.1-2.0 mg/kg.
- the additional therapeutic agent, such as a corticosteroid is administered in a mammalian human at a dose of 0.1-1.0 mg/kg.
- a GVHD patient of the present disclosure is not one who has received or is currently receiving systemic therapy for GVHD, except for corticosteroid therapy within 72 hours.
- GVHD patients of the present disclosure are naive or not receiving systemic therapy for GVHD, except for corticosteroid therapy within 72 hours.
- a patient with GVHD of the present disclosure is naive to systemic treatment for GVHD, or is treated with a corticosteroid within 72 hours.
- the administration frequency of the compound of formula I or its pharmaceutically acceptable salt in the use of the present disclosure is once a day, twice a day, once every two days, once every three days, once every four days, once every five days, once every six days, Once a week, three days a week, once a day, four days a week, once a day, or five days a week, once a day.
- the dosage of the compound of formula I and its pharmaceutically acceptable salt is 2-50 mg in mammals and humans, and the administration frequency is twice a day.
- the corticosteroid is selected from prednisone, methylprednisone, betamethasone, hydrocortisone, dexamethasone, or combinations thereof.
- a compound of Formula I, or a pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent.
- the additional therapeutic agent is selected from a corticosteroid (including without limitation corticotropin, glucocorticoid, or mineralocorticoid), cyclosporine, mycophenolate mofetil, or combinations thereof .
- Another aspect of the present disclosure also provides a method for treating or preventing graft-versus-host disease, which comprises administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to a patient with graft-versus-host disease.
- the dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-50 mg.
- the method of treating or preventing graft-versus-host disease comprises administering to a patient with graft-versus-host disease an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with another therapeutic agent.
- the additional therapeutic agent is a corticosteroid (including but not limited to prednisone, methylprednisone, hydrocortisone, dexamethasone, betamethasone, or beclomethasone dipropionate). In certain embodiments, the additional therapeutic agent is prednisone or methylprednisone.
- “Combination” or “joint use” or “combined administration” in the present disclosure refers to a mode of administration, which refers to the administration of at least one dose of a compound of formula I or a pharmaceutically acceptable salt thereof and at least one dose within a certain period of time.
- the time period can be within one administration cycle, preferably within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours, more preferably within 12 hours.
- the compound of formula I, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent may be administered simultaneously or sequentially.
- This period includes treatments wherein the compound of formula I, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered by the same route of administration or by different routes of administration.
- the administration mode of the combination described in the present application is selected from simultaneous administration, independent formulation and co-administration or independent formulation and sequential administration.
- “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a physiologically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically acceptable carriers and excipients. agent.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
- Partial remission The measurable disease indicators in the affected organs of chronic GVHD are improved or improved by more than 50%, and there is no disease progression in any affected organ or part, and lasts for more than 3 weeks.
- Treatment failure refers to intolerable side effects, disease progression during treatment, no improvement or recurrence after treatment.
- the research population selected patients aged 18 to 70 who received allogeneic peripheral blood hematopoietic stem cell transplantation due to blood system diseases, and were diagnosed with moderate-severe chronic GVHD according to the 2014 chronic GVHD NIH grading criteria;
- Patients may be receiving other immunosuppressants for the prevention or treatment of acute GVHD, but if the subject is receiving prednisone for the prevention or treatment of acute GVHD, it must be ⁇ 0.5mg/kg/d or equivalent dose of other glucocorticoids;
- Drug A (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogen sulfate, tablet (specification: 1mg/tablet, 2mg/tablet, 4mg/tablet) orally, continuous Take orally for at least 4 weeks; unless the disease progresses during treatment, the primary tumor relapses or cannot tolerate the treatment of drug A, the total course of treatment is not less than 6 months; the specific dosage regimen is as follows:
- Drug B prednisone, starting dose 1 mg/kg/day or equivalent dose of methylprednisolone orally once in the morning (maximum adult dose of prednisone 100 mg/day); oral prednisone 1 mg/kg/day if present Intolerance or inappropriate conditions, such as uncontrollable hyperglycemia, hypertension, aseptic necrosis, osteoporosis, severe emotional disorders, etc., the initial dose is 0.5mg/kg/day.
- the overall effective rate (CR+PR) for 28 days of medication is 94.4% (17/18), of which the effective rate of 1mg/day dose group is 66.7%, 2mg/day, 4mg/day, 6mg/day, 8mg/day
- the /daily dose group was 100%; the overall effective rate (CR+PR) was 93.5% (15/16) after 24 weeks of medication.
- the effective rate (about 50%) is higher than the current first-line treatment (glucocorticoid combined with or without calmodulin inhibitor).
- grade ⁇ 3 drug A-related AEs In terms of safety, the incidence of grade ⁇ 3 drug A-related AEs in this study was 22.2%, including 16.7% decrease in platelet count and 5.6% anemia. The short-term drug safety was relatively high, and no new safety risks were added. Compared with similar drug ruxolitinib (the incidence of cGVHD ⁇ grade 3 AE in the treatment of ruxolitinib was 57%, the most common ⁇ grade 3 AE were thrombocytopenia 15.2% and anemia 12.7%), the hematological toxicity was lower. On the other hand, first-line standard therapy for cGVHD had a 56% incidence of grade ⁇ 3 AEs and a 37% incidence of life-threatening/fatal infections.
Abstract
A pyrrolo six-membered heteroaromatic compound or a pharmaceutically acceptable salt thereof for treating or preventing graft-versus-host disease, the structure of which compound being as represented by the following formula: The present invention specifically relates to the use of the pyrrolo six-membered heteroaromatic compound in the preparation of a drug for treating or preventing graft-versus-host disease. The pyrrolo six-membered heteroaromatic compound can improve the effectiveness of graft-versus-host disease therapy, improve the quality of life of patients, and increase the survival rate of patients.
Description
本申请要求申请日为2021年8月12日的中国专利申请2021109254357和申请日为2021年12月1日的中国专利申请2021114521269的优先权。本申请引用上述中国专利申请的全文。This application claims the priority of Chinese patent application 2021109254357 with a filing date of August 12, 2021 and Chinese patent application 2021114521269 with a filing date of December 1, 2021. This application cites the full text of the above-mentioned Chinese patent application.
本公开涉及一种用于治疗或预防抗宿主病的吡咯并六元杂芳物。The present disclosure relates to a pyrrolo six-membered heteroaryl compound for treating or preventing anti-host disease.
移植物抗宿主病(GVHD)通常以发生时间和临床表现分为急性移植物抗宿主病(aGVHD)和慢性移植物抗宿主病(cGVHD)。Graft-versus-host disease (GVHD) is usually divided into acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) based on the time of occurrence and clinical manifestations.
在过去的40年中,皮质类固醇已成为治疗cGvHD的一线方案,即,泼尼松(起始剂量1mg/kg/d)或者等效剂量的甲泼尼龙全身免疫抑制治疗。Over the past 40 years, corticosteroids have become the first-line regimen for the treatment of cGvHD, ie, prednisone (starting dose 1 mg/kg/d) or equivalent doses of methylprednisolone for systemic immunosuppressive therapy.
仅约40%的cGVHD患者对一线治疗有效(包括完全缓解和部分缓解),无反应患者非复发死亡率高出有反应患者约2.5倍。同时研究显示在泼尼松基础上增加钙调素抑制剂(环孢素、普乐可复等)、霉酚酸酯、沙利度胺等药物不能提高一线治疗有效率。Only about 40% of cGVHD patients respond to first-line treatment (including complete remission and partial remission), and the non-relapse mortality rate of non-responding patients is about 2.5 times higher than that of responding patients. At the same time, studies have shown that adding calmodulin inhibitors (cyclosporine, Prograf, etc.), mycophenolate mofetil, and thalidomide to the basis of prednisone cannot improve the efficacy of first-line treatment.
另外,目前还没有标准的二线疗法,用于cGVHD二线治疗的药物包括:mTOR抑制剂、霉酚酸酯、利妥昔单抗、阿仑单抗、沙利度胺、伊马替尼、喷司他丁及甲氨蝶呤等,这些药物可以使部分患者获得缓解,但由于药物强烈的免疫抑制导致真菌、病毒、细菌等感染的发生率明显增加;而且长期应用糖皮质激素会导致糖尿病、骨质疏松、负氮平衡、营养不良。例如,mTOR抑制剂西罗莫司与他克莫司和皮质类固醇激素联合用药,有效率可达63%,但肾毒性值得关注。如何提高中重度cGVHD的一线治疗成功率成为提高移 植后患者生存率的关键因素。In addition, there is currently no standard second-line therapy. The drugs used for the second-line treatment of cGVHD include: mTOR inhibitors, mycophenolate mofetil, rituximab, alemtuzumab, thalidomide, imatinib, spray Sistatin and methotrexate, etc. These drugs can relieve some patients, but due to the strong immunosuppression of the drugs, the incidence of fungal, viral, bacterial and other infections increases significantly; and long-term use of glucocorticoids can lead to diabetes, Osteoporosis, negative nitrogen balance, malnutrition. For example, the mTOR inhibitor sirolimus combined with tacrolimus and corticosteroids has an effective rate of 63%, but nephrotoxicity is a concern. How to improve the success rate of first-line treatment of moderate to severe cGVHD has become a key factor in improving the survival rate of patients after transplantation.
cGVHD的发病机制仍然在不断地探索中,过去的研究基础表明由于持久存在同种异体反应性T细胞,产生针对宿主抗原的自身或同种抗体的B细胞,以及供体抗原呈递细胞(APC)的作用替代宿主APC,从而导致同种异体抗原的间接呈递,造成皮肤、胃肠道及肝脏等靶器官的损害。cGVHD过程中,T淋巴细胞、树突状细胞、NK细胞、巨噬细胞等作为主要的效应细胞活化、增殖,并且释放大量的炎症细胞因子诱导靶器官细胞凋亡,导致靶器官组织的损伤。而移植后免疫缺陷所致的并发症和长期应用免疫抑制剂又会加重这种紊乱状态,所以其相互作用机制仍需进一步研究。The pathogenesis of cGVHD is still under investigation, with past research based on the persistence of alloreactive T cells, B cells that produce self or alloantibodies against host antigens, and donor antigen-presenting cells (APCs) The role of the host to replace the host APC, resulting in the indirect presentation of alloantigens, causing damage to target organs such as the skin, gastrointestinal tract and liver. In the process of cGVHD, T lymphocytes, dendritic cells, NK cells, macrophages, etc. are activated and proliferate as the main effector cells, and release a large amount of inflammatory cytokines to induce apoptosis of target organ cells, resulting in damage to target organ tissues. Complications caused by immunodeficiency after transplantation and long-term application of immunosuppressants will aggravate this disorder, so the interaction mechanism still needs further study.
已有研究证实,JAK抑制剂在GVHD发生的炎症反应及组织损伤中发挥了重要作用。同时JAK抑制剂能够阻断JAK-STAT分子通路,降低炎症细胞因子的水平,即使在JAK突变阴性的患者中也有效果。Studies have confirmed that JAK inhibitors play an important role in the inflammatory response and tissue damage of GVHD. At the same time, JAK inhibitors can block the JAK-STAT molecular pathway and reduce the level of inflammatory cytokines, even in patients with negative JAK mutations.
例如,Ruxolitinib、Baricitinib等在部分GVHD患者中已有一些临床经验,其中Ruxolitinib被批准用于治疗12岁及以上成人和儿童患者的类固醇难治性急性GVHD。一项研究中回顾性分析了Ruxolitinib在41例甾体难治性慢性GVHD患者中的使用情况:慢性GVHD患者总反应率为85%,中位反应时间为3周,GVHD的靶器官有所改善。For example, Ruxolitinib, Baricitinib, etc. have some clinical experience in some GVHD patients, among which Ruxolitinib is approved for the treatment of steroid-refractory acute GVHD in adults and children aged 12 and over. A study retrospectively analyzed the use of Ruxolitinib in 41 steroid-refractory chronic GVHD patients: the overall response rate of patients with chronic GVHD was 85%, the median response time was 3 weeks, and the target organs of GVHD improved .
(3aR,5s,6aS)-N-(3-甲氧基-1,2,4-噻二唑-5-基)-5-(甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基)六氢环戊并[c]吡咯-2(1H)-甲酰胺为一类具有体内、外活性,高吸收的JAK激酶抑制剂化合物,(3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine -4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide is a class of JAK kinase inhibitor compounds with in vivo and in vitro activity and high absorption,
然而未见该分子能有效用于治疗或预防移 植物宿主病的临床报道。
However, there is no clinical report that this molecule can be effectively used in the treatment or prevention of graft-host disease.
发明内容Contents of the invention
本公开(The disclosure)提供了式I所示化合物或其可药用盐在制备用于治疗或预防移植物抗宿主病的药物中的用途,The disclosure (The disclosure) provides the use of the compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing graft-versus-host disease,
在一些实施方案中,所述移植物抗宿主病为慢性移植物抗宿主病。参照2014年NIH慢性移植物抗宿主病的诊断和疗效分级标准进行分级,包括轻度移植物抗宿主病、中度移植物抗宿主病和重度移植物抗宿主病。在一些实施方案中,所述移植物抗宿主病为中度移植物抗宿主病。在一些实施方案中,所述移植物抗宿主病为中度以上移植物抗宿主病。在一些实施方案中,所述移植物抗宿主病为中度-重度移植物抗宿主病。在一些实施方案中,所述移植物抗宿主病为重度移植物抗宿主病。In some embodiments, the graft versus host disease is chronic graft versus host disease. According to the 2014 NIH chronic graft-versus-host disease diagnosis and curative effect grading standards, it is graded, including mild graft-versus-host disease, moderate graft-versus-host disease and severe graft-versus-host disease. In some embodiments, the graft versus host disease is moderate graft versus host disease. In some embodiments, the graft-versus-host disease is more than moderate graft-versus-host disease. In some embodiments, the graft versus host disease is moderate-severe graft versus host disease. In some embodiments, the graft versus host disease is severe graft versus host disease.
另一方面,本公开中移植物抗宿主病患者为已经接受细胞移植的。在某一些实施方案中,移植物抗宿主病患者为异基因骨髓或造血干细胞移植的。In another aspect, a patient with graft-versus-host disease in the present disclosure is one who has undergone cell transplantation. In certain embodiments, the patient with graft versus host disease has undergone allogeneic bone marrow or hematopoietic stem cell transplantation.
在一些实施方案中,根据患者体重给药,式I化合物或其可药用盐在哺乳动物人中的施用剂量为0.1~10.0mg/kg,具体为0.1mg/kg、0.2mg/kg、0.3mg/kg、0.4mg/kg、0.5mg/kg、0.6mg/kg、0.7mg/kg、0.8mg/kg、0.9mg/kg、1.0mg/kg、1.2mg/kg、1.4mg/kg、1.6mg/kg、1.8mg/kg、2.0mg/kg、2.2mg/kg、2.4mg/kg、2.6mg/kg、2.8mg/kg、3.0mg/kg、3.2mg/kg、3.4mg/kg、3.6mg/kg、 3.8mg/kg、4.0mg/kg、4.2mg/kg、4.4mg/kg、4.6mg/kg、4.8mg/kg、5.0mg/kg、5.2mg/kg、5.4mg/kg、5.6mg/kg、5.8mg/kg、6.0mg/kg、6.2mg/kg、6.4mg/kg、6.6mg/kg、6.8mg/kg、7.0mg/kg、7.2mg/kg、7.4mg/kg、7.6mg/kg、7.8mg/kg、8.0mg/kg、8.2mg/kg、8.4mg/kg、8.6mg/kg、8.8mg/kg、9.0mg/kg、9.2mg/kg、9.4mg/kg、9.6mg/kg、9.8mg/kg、10.0mg/kg或任意两数值间任意值。In some embodiments, administration is based on the patient's body weight, and the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 0.1-10.0 mg/kg, specifically 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4mg/kg, 0.5mg/kg, 0.6mg/kg, 0.7mg/kg, 0.8mg/kg, 0.9mg/kg, 1.0mg/kg, 1.2mg/kg, 1.4mg/kg, 1.6 mg/kg, 1.8mg/kg, 2.0mg/kg, 2.2mg/kg, 2.4mg/kg, 2.6mg/kg, 2.8mg/kg, 3.0mg/kg, 3.2mg/kg, 3.4mg/kg, 3.6 mg/kg, 3.8mg/kg, 4.0mg/kg, 4.2mg/kg, 4.4mg/kg, 4.6mg/kg, 4.8mg/kg, 5.0mg/kg, 5.2mg/kg, 5.4mg/kg, 5.6 mg/kg, 5.8mg/kg, 6.0mg/kg, 6.2mg/kg, 6.4mg/kg, 6.6mg/kg, 6.8mg/kg, 7.0mg/kg, 7.2mg/kg, 7.4mg/kg, 7.6 mg/kg, 7.8mg/kg, 8.0mg/kg, 8.2mg/kg, 8.4mg/kg, 8.6mg/kg, 8.8mg/kg, 9.0mg/kg, 9.2mg/kg, 9.4mg/kg, 9.6 mg/kg, 9.8mg/kg, 10.0mg/kg or any value between any two values.
在另一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为0.1~5.0mg/kg。在另一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为1.0~5.0mg/kg。在另一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为4.0~6.0mg/kg。在另一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为5.0~6.0mg/kg。In other embodiments, the dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 0.1-5.0 mg/kg. In other embodiments, the dose of the compound of formula I or its pharmaceutically acceptable salt in mammals is 1.0-5.0 mg/kg. In other embodiments, the dose of the compound of formula I or its pharmaceutically acceptable salt in mammals is 4.0-6.0 mg/kg. In other embodiments, the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 5.0-6.0 mg/kg.
在一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为1~50mg,具体为1.0mg、1.2mg、1.4mg、1.6mg、1.8mg、2.0mg、2.2mg、2.4mg、2.6mg、2.8mg、3.0mg、3.2mg、3.4mg、3.6mg、3.8mg、4.0mg、4.2mg、4.4mg、4.6mg、4.8mg、5.0mg、5.2mg、5.4mg、5.6mg、5.8mg、6.0mg、6.2mg、6.4mg、6.6mg、6.8mg、7.0mg、7.2mg、7.4mg、7.6mg、7.8mg、8.0mg、8.2mg、8.4mg、8.6mg、8.8mg、9.0mg、9.2mg、9.4mg、9.6mg、9.8mg、10.0mg、15mg、20mg、25mg、30mg、35mg、40mg、45mg、50mg或任意两数值间任意值,优选2mg、4mg、6mg或10mg。In some embodiments, the dosage of the compound of formula I or its pharmaceutically acceptable salt in mammals is 1-50 mg, specifically 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2.0 mg, 2.2 mg , 2.4mg, 2.6mg, 2.8mg, 3.0mg, 3.2mg, 3.4mg, 3.6mg, 3.8mg, 4.0mg, 4.2mg, 4.4mg, 4.6mg, 4.8mg, 5.0mg, 5.2mg, 5.4mg, 5.6 mg, 5.8mg, 6.0mg, 6.2mg, 6.4mg, 6.6mg, 6.8mg, 7.0mg, 7.2mg, 7.4mg, 7.6mg, 7.8mg, 8.0mg, 8.2mg, 8.4mg, 8.6mg, 8.8mg, 9.0mg, 9.2mg, 9.4mg, 9.6mg, 9.8mg, 10.0mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg or any value between any two values, preferably 2mg, 4mg, 6mg or 10mg.
在某些实施方案中,式I化合物或其可药用盐在哺乳动物人中的日施用剂量为2~10mg。在某些实施方案中,式I化合物或其可药用盐在哺乳动物人中的日施用剂量为2~5mg。在某些实施方案中,式I化合物或其可药用盐在哺乳动物人中的日施用剂量为4~8mg。In certain embodiments, the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-10 mg. In certain embodiments, the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-5 mg. In certain embodiments, the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 4-8 mg.
在另一些实施方案中,式I化合物或其可药用盐以药物组合物形式给药,所述组合物为1mg剂量形式。In other embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof is administered in the form of a pharmaceutical composition, which is in the form of a 1 mg dosage.
在一些实施方案中,式I化合物或其可药用盐以药物组合物形式给药, 所述组合物为2mg剂量形式。In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition in the form of a 2 mg dosage.
在一些实施方案中,式I化合物或其可药用盐以药物组合物形式给药,所述组合物为4mg剂量形式。In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition in the form of a 4 mg dosage.
在一些实施方案中,式I化合物或其可药用盐以药物组合物形式给药,所述组合物为6mg剂量形式。In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition in the form of a 6 mg dosage.
在一些实施方案中,式I化合物或其可药用盐以药物组合物形式给药,所述组合物为8mg剂量形式。In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition in an 8 mg dosage form.
在另一些实施方案中,给药剂量、施用剂量或单位剂量以游离碱计。In other embodiments, the administered dose, administered dose or unit dose is based on free base.
在一些实施方案中,所述药物组合物包含式I化合物或其可药用盐以及一种或多种可药用的赋形剂、稀释剂或载体。In some embodiments, the pharmaceutical composition comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.
另一方面,本公开的用途中所述式I化合物或其可药用盐与一种或多种另外的治疗剂组合施用。In another aspect, in the disclosed uses, the compound of formula I or a pharmaceutically acceptable salt thereof is administered in combination with one or more additional therapeutic agents.
在一些实施方案中,另外的治疗剂选自皮质类激素(包括不限于促肾上腺皮质激素、糖皮质激素或盐皮质激素)、环孢菌素、霉酚酸吗啉乙酯或其组合。In some embodiments, the additional therapeutic agent is selected from a corticosteroid (including without limitation corticotropin, glucocorticoid, or mineralocorticoid), cyclosporine, mycophenolate mofetil, or combinations thereof.
在某些实施方案中,另外的治疗剂为皮质类激素(包括但不限于泼尼松、甲基泼尼松、氢化可的松、地塞米松、倍他米松或丙酸倍氯米松)。在某些实施方案中,另外的治疗剂为泼尼松或甲基泼尼松。In certain embodiments, the additional therapeutic agent is a corticosteroid (including but not limited to prednisone, methylprednisone, hydrocortisone, dexamethasone, betamethasone, or beclomethasone dipropionate). In certain embodiments, the additional therapeutic agent is prednisone or methylprednisone.
进一步地,所述式I化合物或其可药用盐联合另外的治疗剂具有协同药效作用。能有效降低式I化合物或其可药用盐单独施用剂量,减少药物如甲基泼尼松或泼尼松的不良反应。Further, the compound of formula I or a pharmaceutically acceptable salt thereof in combination with another therapeutic agent has a synergistic pharmacological effect. It can effectively reduce the single dose of the compound of formula I or its pharmaceutically acceptable salt, and reduce the adverse reactions of drugs such as methylprednisone or prednisone.
在一些实施方案中,另外的治疗剂如皮质激素,根据患者体重给药,在哺乳动物人中的施用剂量为0.1~10.0mg/kg,具体为0.1mg/kg、0.2mg/kg、0.3mg/kg、0.4mg/kg、0.5mg/kg、0.6mg/kg、0.7mg/kg、0.8mg/kg、0.9mg/kg、1.0mg/kg、1.2mg/kg、1.4mg/kg、1.6mg/kg、1.8mg/kg、2.0mg/kg、2.2mg/kg、 2.4mg/kg、2.6mg/kg、2.8mg/kg、3.0mg/kg、3.2mg/kg、3.4mg/kg、3.6mg/kg、3.8mg/kg、4.0mg/kg、4.2mg/kg、4.4mg/kg、4.6mg/kg、4.8mg/kg、5.0mg/kg、5.2mg/kg、5.4mg/kg、5.6mg/kg、5.8mg/kg、6.0mg/kg、6.2mg/kg、6.4mg/kg、6.6mg/kg、6.8mg/kg、7.0mg/kg、7.2mg/kg、7.4mg/kg、7.6mg/kg、7.8mg/kg、8.0mg/kg、8.2mg/kg、8.4mg/kg、8.6mg/kg、8.8mg/kg、9.0mg/kg、9.2mg/kg、9.4mg/kg、9.6mg/kg、9.8mg/kg、10.0mg/kg或任意两数值间任意值。In some embodiments, additional therapeutic agents such as corticosteroids are administered according to the body weight of the patient, and the dosage in mammals is 0.1-10.0 mg/kg, specifically 0.1 mg/kg, 0.2 mg/kg, 0.3 mg /kg, 0.4mg/kg, 0.5mg/kg, 0.6mg/kg, 0.7mg/kg, 0.8mg/kg, 0.9mg/kg, 1.0mg/kg, 1.2mg/kg, 1.4mg/kg, 1.6mg /kg, 1.8mg/kg, 2.0mg/kg, 2.2mg/kg, 2.4mg/kg, 2.6mg/kg, 2.8mg/kg, 3.0mg/kg, 3.2mg/kg, 3.4mg/kg, 3.6mg /kg, 3.8mg/kg, 4.0mg/kg, 4.2mg/kg, 4.4mg/kg, 4.6mg/kg, 4.8mg/kg, 5.0mg/kg, 5.2mg/kg, 5.4mg/kg, 5.6mg /kg, 5.8mg/kg, 6.0mg/kg, 6.2mg/kg, 6.4mg/kg, 6.6mg/kg, 6.8mg/kg, 7.0mg/kg, 7.2mg/kg, 7.4mg/kg, 7.6mg /kg, 7.8mg/kg, 8.0mg/kg, 8.2mg/kg, 8.4mg/kg, 8.6mg/kg, 8.8mg/kg, 9.0mg/kg, 9.2mg/kg, 9.4mg/kg, 9.6mg /kg, 9.8mg/kg, 10.0mg/kg or any value between any two values.
在另一些实施方案中,另外的治疗剂如皮质激素在哺乳动物人中的施用剂量为0.1~10.0mg/kg。在另一些实施方案中,另外的治疗剂如皮质激素在哺乳动物人中的施用剂量为1.0~2.0mg/kg。在另一些实施方案中,另外的治疗剂如皮质激素在哺乳动物人中的施用剂量为0.1~2.0mg/kg。在另一些实施方案中,另外的治疗剂如皮质激素在哺乳动物人中的施用剂量为0.1~1.0mg/kg。In other embodiments, the additional therapeutic agent, such as a corticosteroid, is administered in a mammalian human at a dose of 0.1-10.0 mg/kg. In other embodiments, the additional therapeutic agent, such as a corticosteroid, is administered in a mammalian human at a dose of 1.0-2.0 mg/kg. In other embodiments, the additional therapeutic agent, such as a corticosteroid, is administered in a mammalian human at a dose of 0.1-2.0 mg/kg. In other embodiments, the additional therapeutic agent, such as a corticosteroid, is administered in a mammalian human at a dose of 0.1-1.0 mg/kg.
在一些实施方案中,本公开移植物抗宿主病患者不为已接受过或正在接受对移植物抗宿主病全身治疗的,除了在72小时内接受皮质类激素治疗的。In some embodiments, a GVHD patient of the present disclosure is not one who has received or is currently receiving systemic therapy for GVHD, except for corticosteroid therapy within 72 hours.
在另一些实施方案中,本公开移植物抗宿主病患者为未接受过或没有正在接受对移植物抗宿主病全身治疗的,除了在72小时内接受皮质类激素治疗的。In other embodiments, GVHD patients of the present disclosure are naive or not receiving systemic therapy for GVHD, except for corticosteroid therapy within 72 hours.
在某些实施方案中,本公开移植物抗宿主病患者为未接受过对移植物抗宿主病全身治疗的,或者在72小时内接受皮质类激素治疗的。In certain embodiments, a patient with GVHD of the present disclosure is naive to systemic treatment for GVHD, or is treated with a corticosteroid within 72 hours.
另一方面,本公开用途中式I化合物或其可药用盐的给药频率为一日一次,一日两次,两天一次,三天一次,四天一次,五天一次,六天一次,一周一次,每周给药三天、一天一次,每周给药四天、一天一次,或者每周给药五天、一天一次。On the other hand, the administration frequency of the compound of formula I or its pharmaceutically acceptable salt in the use of the present disclosure is once a day, twice a day, once every two days, once every three days, once every four days, once every five days, once every six days, Once a week, three days a week, once a day, four days a week, once a day, or five days a week, once a day.
在一些实施方案中,式I化合物其可药用盐在哺乳动物人中的施用剂量为2~50mg,给药频率为一日一次。In some embodiments, the dosage of the compound of formula I and its pharmaceutically acceptable salt in mammals is 2-50 mg, and the administration frequency is once a day.
在一些实施方案中,式I化合物其可药用盐在哺乳动物人中的施用剂量为2~50mg,给药频率为一日二次。In some embodiments, the dosage of the compound of formula I and its pharmaceutically acceptable salt is 2-50 mg in mammals and humans, and the administration frequency is twice a day.
在一些实施方案中,式I化合物其可药用盐在哺乳动物人中的施用剂量为4mg,给药频率为一日一次。In some embodiments, the dosage of the compound of formula I and its pharmaceutically acceptable salt in mammals is 4 mg, and the administration frequency is once a day.
在一些实施方案中,式I化合物其可药用盐在哺乳动物人中的施用剂量为4mg,给药频率为一日二次。In some embodiments, the dose of the compound of formula I and its pharmaceutically acceptable salt in mammals is 4 mg, and the administration frequency is twice a day.
本公开另一方面还提供了式I所示化合物或其可药用盐与皮质类激素在制备用于治疗或预防移植物抗宿主病的药物中的用途,Another aspect of the present disclosure also provides the use of a compound represented by formula I or a pharmaceutically acceptable salt thereof and a corticosteroid in the preparation of a medicament for treating or preventing graft-versus-host disease,
在一些实施方案中,所述皮质类激素选自泼尼松、甲基泼尼松、倍他米松、氢化可的松、地塞米松或其组合。In some embodiments, the corticosteroid is selected from prednisone, methylprednisone, betamethasone, hydrocortisone, dexamethasone, or combinations thereof.
本公开另一方面还提供了用于治疗或预防移植物抗宿主病的式I化合物或其可药用盐,Another aspect of the present disclosure also provides a compound of formula I or a pharmaceutically acceptable salt thereof for treating or preventing graft-versus-host disease,
在一些实施方案中,式I化合物或其可药用盐与另外的治疗剂组合施用。在某些实施方案中,所述另外治疗剂选自皮质类激素(包括不限于促肾上腺皮质激素、糖皮质激素或盐皮质激素)、环孢菌素、霉酚酸吗啉乙酯或其组 合。In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered in combination with an additional therapeutic agent. In certain embodiments, the additional therapeutic agent is selected from a corticosteroid (including without limitation corticotropin, glucocorticoid, or mineralocorticoid), cyclosporine, mycophenolate mofetil, or combinations thereof .
本公开另一方面还提供一种治疗或预防移植物抗宿主病的方法,其包括向移植物抗宿主病患者施用有效量的式I化合物或其可药用盐。在一些实施方案中,式I化合物或其可药用盐在哺乳动物人中的施用剂量为2~50mg。Another aspect of the present disclosure also provides a method for treating or preventing graft-versus-host disease, which comprises administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to a patient with graft-versus-host disease. In some embodiments, the dose of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is 2-50 mg.
在另一些实施方案中,治疗或预防移植物抗宿主病的方法包括向移植物抗宿主病患者组合施用有效量的式I化合物或其可药用盐与另外的治疗剂。In other embodiments, the method of treating or preventing graft-versus-host disease comprises administering to a patient with graft-versus-host disease an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with another therapeutic agent.
在某些实施方案中,另外的治疗剂为皮质类激素(包括但不限于泼尼松、甲基泼尼松、氢化可的松、地塞米松、倍他米松或丙酸倍氯米松)。在某些实施方案中,另外的治疗剂为泼尼松或甲基泼尼松。In certain embodiments, the additional therapeutic agent is a corticosteroid (including but not limited to prednisone, methylprednisone, hydrocortisone, dexamethasone, betamethasone, or beclomethasone dipropionate). In certain embodiments, the additional therapeutic agent is prednisone or methylprednisone.
在一些实施方案中,本公开式I化合物的可药用盐包括但不限于硫酸氢盐或硫酸盐。In some embodiments, pharmaceutically acceptable salts of compounds of formula I of the present disclosure include, but are not limited to, bisulfate or sulfate salts.
本公开还提供一种用于治疗移植物抗宿主病的药物组合,其包含有效治疗量的式I化合物或其可药用盐。进一步地,所述药物组合还包括另外的治疗剂。The present disclosure also provides a pharmaceutical combination for treating graft-versus-host disease, which comprises a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. Further, the pharmaceutical combination also includes another therapeutic agent.
如无相反解释,本公开中术语具有如下含义:Unless otherwise explained, terms in this disclosure have the following meanings:
本公开关于“联合”或“联用”或“组合施用”是一种给药方式,是指在一定时间期限内给予至少一种剂量的式I化合物或其可药用盐和至少一种剂量的另外的治疗剂,其中两种物质都显示药理学作用。所述的时间期限可以是一个给药周期内,优选4周内,3周内,2周内,1周内,或24小时以内,更优选12小时以内。可以同时或依次给予式I化合物或其可药用盐和另外的治疗剂。这种期限包括这样的治疗,其中通过相同给药途径或不同给药途径给予式I化合物或其可药用盐和另外的治疗剂。本申请所述联合的给药方式选自同时给药、独立地配制并共给药或独立地配制并相继给药。"Combination" or "joint use" or "combined administration" in the present disclosure refers to a mode of administration, which refers to the administration of at least one dose of a compound of formula I or a pharmaceutically acceptable salt thereof and at least one dose within a certain period of time. An additional therapeutic agent for which both substances exhibit pharmacological effects. The time period can be within one administration cycle, preferably within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours, more preferably within 12 hours. The compound of formula I, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent may be administered simultaneously or sequentially. This period includes treatments wherein the compound of formula I, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered by the same route of administration or by different routes of administration. The administration mode of the combination described in the present application is selected from simultaneous administration, independent formulation and co-administration or independent formulation and sequential administration.
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上可药用盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学可药 用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。"Pharmaceutical composition" means a mixture containing one or more compounds described herein, or a physiologically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically acceptable carriers and excipients. agent. The purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
本公开中所述“有效量”或“有效治疗量”包含足以改善或预防医学病症的症状或病症的量。有效量还意指足以允许或促进诊断的量。用于特定患者或兽医学受试者的有效量可依据以下因素而变化:如待治疗的病症、患者的总体健康情况、给药的方法途径和剂量以及副作用严重性。有效量可以是避免显著副作用或毒性作用的最大剂量或给药方案。An "effective amount" or "therapeutically effective amount" as used in the present disclosure includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. Effective amounts for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the method, route and dosage of administration, and the severity of side effects. An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
完全缓解(CR):慢性GVHD的症状完全消失,且持续3周以上。Complete remission (CR): The symptoms of chronic GVHD disappear completely and last for more than 3 weeks.
部分缓解(PR):慢性GVHD受累器官中可测量的疾病指标改善或好转50%以上,没有任一受累器官或部位疾病进展,且持续3周以上。Partial remission (PR): The measurable disease indicators in the affected organs of chronic GVHD are improved or improved by more than 50%, and there is no disease progression in any affected organ or part, and lasts for more than 3 weeks.
治疗无效:慢性GVHD的症状无改善,任一器官的严重程度加重至少一个级别,新出现某个器官的慢性GVHD,需要加用其他药物治疗慢性GVHD。Ineffective treatment: the symptoms of chronic GVHD do not improve, the severity of any organ is aggravated by at least one level, chronic GVHD of a certain organ appears newly, and other drugs need to be added to treat chronic GVHD.
治疗失败:是指毒副作用不可耐受、治疗过程中疾病进展、无改善或治疗结束后复发。Treatment failure: refers to intolerable side effects, disease progression during treatment, no improvement or recurrence after treatment.
以下结合实施例用于进一步描述本公开,但这些实施例并非限制本公开的范围。The following examples are used to further describe the present disclosure, but these examples do not limit the scope of the present disclosure.
实施例1Example 1
研究人群选取18岁至70岁、因血液系统疾病接受异基因外周血造血干细胞移植的患者,依据2014慢性GVHD NIH分级标准评估,诊断为中度-重度的慢性GVHD;The research population selected patients aged 18 to 70 who received allogeneic peripheral blood hematopoietic stem cell transplantation due to blood system diseases, and were diagnosed with moderate-severe chronic GVHD according to the 2014 chronic GVHD NIH grading criteria;
已经开始激素治疗的慢性GVHD时间不超过72小时;Chronic GVHD that has started hormone therapy for no more than 72 hours;
患者可能正在接受其他免疫抑制剂预防或治疗急性GVHD,但如果受试者接受泼尼松预防或治疗急性GVHD,则必须<0.5mg/kg/d或等效剂量其他糖皮质激素;Patients may be receiving other immunosuppressants for the prevention or treatment of acute GVHD, but if the subject is receiving prednisone for the prevention or treatment of acute GVHD, it must be <0.5mg/kg/d or equivalent dose of other glucocorticoids;
且排除接受任何对cGVHD的全身治疗,除了在签署知情同意书前72h内给予治疗cGVHD的皮质类固醇。And exclude any systemic treatment for cGVHD, except for corticosteroids for cGVHD within 72 hours before signing the informed consent.
给药方案:Dosing regimen:
药物A:(3aR,5s,6aS)-N-(3-甲氧基-1,2,4-噻二唑-5-基)-5-(甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基)六氢环戊并[c]吡咯-2(1H)-甲酰胺硫酸氢,片剂(规格:1mg/片、2mg/片、4mg/片)口服,连续口服至少4周;除非治疗过程中疾病进展、原发肿瘤复发或不能耐受药物A治疗,总疗程不少于6月;具体给药方案如下:Drug A: (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3- d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogen sulfate, tablet (specification: 1mg/tablet, 2mg/tablet, 4mg/tablet) orally, continuous Take orally for at least 4 weeks; unless the disease progresses during treatment, the primary tumor relapses or cannot tolerate the treatment of drug A, the total course of treatment is not less than 6 months; the specific dosage regimen is as follows:
组别group | 剂量/日Dose/day |
11 | 1mg/日1mg/day |
22 | 2mg/日2mg/day |
33 | 4mg/日4mg/day |
44 | 6mg/日6mg/day |
55 | 8mg/日8mg/day |
药物物B:泼尼松,起始剂量1mg/kg/日或等效剂量甲泼尼龙早上一次口服(强的松成人最大剂量100mg/日);如果患者存在口服泼尼松1mg/kg/日不耐受或不适当情况,如难以控制的高血糖、高血压、无菌性坏死、骨质疏松、严重情感障碍等,起始剂量0.5mg/kg/日。Drug B: prednisone, starting dose 1 mg/kg/day or equivalent dose of methylprednisolone orally once in the morning (maximum adult dose of prednisone 100 mg/day); oral prednisone 1 mg/kg/day if present Intolerance or inappropriate conditions, such as uncontrollable hyperglycemia, hypertension, aseptic necrosis, osteoporosis, severe emotional disorders, etc., the initial dose is 0.5mg/kg/day.
结论:基于可评价患者,用药28天总体有效率(CR+PR)94.4%(17/18),其中1mg/日剂量组有效率66.7%,2mg/日、4mg/日、6mg/日、8mg/日剂量组均为100%;用药24周总体有效率(CR+PR)93.5%(15/16)。高于目前一 线治疗(糖皮质激素联合或不联合钙调神经蛋白抑制剂)的有效率(约为50%)。Conclusion: Based on evaluable patients, the overall effective rate (CR+PR) for 28 days of medication is 94.4% (17/18), of which the effective rate of 1mg/day dose group is 66.7%, 2mg/day, 4mg/day, 6mg/day, 8mg/day The /daily dose group was 100%; the overall effective rate (CR+PR) was 93.5% (15/16) after 24 weeks of medication. The effective rate (about 50%) is higher than the current first-line treatment (glucocorticoid combined with or without calmodulin inhibitor).
安全性方面,本研究≥3级与药物A相关AE发生率22.2%,其中血小板计数降低16.7%、贫血5.6%,短期用药安全性较高,未增加新的安全性风险。与同类药物芦可替尼(芦可替尼治疗cGVHD≥3级AE发生率57%,最常见≥3级AE为血小板减少15.2%和贫血12.7%)相比,血液学毒性更低。另一方面,cGVHD一线标准治疗≥3级AE发生率56%,危及生命/致命的感染发生率37%。In terms of safety, the incidence of grade ≥3 drug A-related AEs in this study was 22.2%, including 16.7% decrease in platelet count and 5.6% anemia. The short-term drug safety was relatively high, and no new safety risks were added. Compared with similar drug ruxolitinib (the incidence of cGVHD ≥ grade 3 AE in the treatment of ruxolitinib was 57%, the most common ≥ grade 3 AE were thrombocytopenia 15.2% and anemia 12.7%), the hematological toxicity was lower. On the other hand, first-line standard therapy for cGVHD had a 56% incidence of grade ≥3 AEs and a 37% incidence of life-threatening/fatal infections.
Claims (15)
- 根据权利要求1所述的用途,其中所述移植物抗宿主病为慢性移植物抗宿主病。The use according to claim 1, wherein the graft-versus-host disease is chronic graft-versus-host disease.
- 根据权利要求1或2所述的用途,其中所述移植物抗宿主病为中度-重度移植物抗宿主病,优选中度-重度慢性移植物抗宿主病。The use according to claim 1 or 2, wherein the graft-versus-host disease is moderate-severe graft-versus-host disease, preferably moderate-severe chronic graft-versus-host disease.
- 根据权利要求1-3任一项所述的用途,其中患者为已经接受细胞移植的,所述细胞移植优选异基因骨髓或造血干细胞移植的。The use according to any one of claims 1-3, wherein the patient has received cell transplantation, and the cell transplantation is preferably allogeneic bone marrow or hematopoietic stem cell transplantation.
- 根据权利要求1-4任一项所述的用途,其中所述式I化合物或其可药用盐在哺乳动物人中的施用剂量选自1~50mg,优选2mg、4mg、6mg或10mg。The use according to any one of claims 1-4, wherein the dosage of the compound of formula I or a pharmaceutically acceptable salt thereof in mammals is selected from 1-50 mg, preferably 2 mg, 4 mg, 6 mg or 10 mg.
- 根据权利要求1-5任一项所述的用途,其中所述式I化合物或其可药用盐给药方式为一日一次或一日两次。The use according to any one of claims 1-5, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is administered once a day or twice a day.
- 根据权利要求1-6任一项所述的用途,其中所述式I化合物或其可药用盐与一种或多种另外的治疗剂组合施用。The use according to any one of claims 1-6, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is administered in combination with one or more additional therapeutic agents.
- 根据权利要求7所述的用途,其中所述另外的治疗剂选自皮质类激素、环孢菌素、霉酚酸吗啉乙酯或其组合,优选皮质类激素,更优选泼尼松或甲基泼尼松。The use according to claim 7, wherein the additional therapeutic agent is selected from corticosteroids, cyclosporine, mycophenolate mofetil or combinations thereof, preferably corticosteroids, more preferably prednisone or formazan base prednisone.
- 根据权利要求1-8任一项所述的用途,其中移植物抗宿主病患者不为已接受过或正在接受对移植物抗宿主病全身治疗的,除非在72小时内接受皮质类激素治疗的。The use according to any one of claims 1-8, wherein the patient with graft-versus-host disease has not received or is receiving systemic treatment for graft-versus-host disease, unless receiving corticosteroid therapy within 72 hours .
- 根据权利要求1-8任一项所述的用途,其中移植物抗宿主病患者为未接受过对移植物抗宿主病全身治疗的,或者接受皮质类激素治疗不超过72小时的。The use according to any one of claims 1-8, wherein the patient with graft-versus-host disease has not received systemic treatment for graft-versus-host disease, or has received corticosteroid therapy for no more than 72 hours.
- 根据权利要求11所述的用途,其中所述皮质类激素选自泼尼松、 甲基泼尼松、倍他米松、氢化可的松、地塞米松或其组合。The use according to claim 11, wherein the corticosteroid is selected from prednisone, methylprednisone, betamethasone, hydrocortisone, dexamethasone or a combination thereof.
- 根据权利要求1或11所述的用途,其中式I所示化合物的可药用盐为硫酸氢盐或硫酸盐。The use according to claim 1 or 11, wherein the pharmaceutically acceptable salt of the compound shown in formula I is bisulfate or sulfate.
- 根据权利要求14所述的式I化合物或其可药用盐,其与一种或多种另外的治疗剂组合施用。A compound of formula I, or a pharmaceutically acceptable salt thereof, according to claim 14, which is administered in combination with one or more additional therapeutic agents.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110925435.7 | 2021-08-12 | ||
CN202110925435 | 2021-08-12 | ||
CN202111452126 | 2021-12-01 | ||
CN202111452126.9 | 2021-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023016551A1 true WO2023016551A1 (en) | 2023-02-16 |
Family
ID=85199891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/112101 WO2023016551A1 (en) | 2021-08-12 | 2022-08-12 | Pyrrolo six-membered heteroaromatic compound for treating or preventing graft-versus-host disease |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202320788A (en) |
WO (1) | WO2023016551A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105566327A (en) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | JAK kinase inhibitor bisulfate crystal type I and preparation method thereof |
US20180222912A1 (en) * | 2011-12-21 | 2018-08-09 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole heteroaryl ring derivative and method of use thereof |
US20190308972A1 (en) * | 2016-11-23 | 2019-10-10 | Jiangsu Hengrui Medicine Co., Ltd. | Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative |
US20200276109A1 (en) * | 2017-11-20 | 2020-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition for topical administration and preparation method therefor |
WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
CN113440613A (en) * | 2020-03-26 | 2021-09-28 | 轶诺(浙江)药业有限公司 | Application of berberine analogue and JAK inhibitor in treatment of gastrointestinal inflammatory diseases |
-
2022
- 2022-08-12 TW TW111130499A patent/TW202320788A/en unknown
- 2022-08-12 WO PCT/CN2022/112101 patent/WO2023016551A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180222912A1 (en) * | 2011-12-21 | 2018-08-09 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole heteroaryl ring derivative and method of use thereof |
CN105566327A (en) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | JAK kinase inhibitor bisulfate crystal type I and preparation method thereof |
US20190308972A1 (en) * | 2016-11-23 | 2019-10-10 | Jiangsu Hengrui Medicine Co., Ltd. | Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative |
US20200276109A1 (en) * | 2017-11-20 | 2020-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition for topical administration and preparation method therefor |
WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
CN113440613A (en) * | 2020-03-26 | 2021-09-28 | 轶诺(浙江)药业有限公司 | Application of berberine analogue and JAK inhibitor in treatment of gastrointestinal inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
TW202320788A (en) | 2023-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chighizola et al. | The use of cyclosporine A in rheumatology: a 2016 comprehensive review | |
JP6712427B2 (en) | Methods of treating and preventing graft-versus-host disease | |
KR20180113976A (en) | Concurrent therapy of tetracycline quinolone analogs to treat cancer | |
KR102537990B1 (en) | Cannabidiol for reduction of steroid doses and treatment of inflammation and autoimmune diseases | |
AU2022202508A1 (en) | Treatment of alopecia areata | |
JP2005522466A (en) | Combination of aldosterone receptor antagonist and nicotinic acid or nicotinic acid derivative | |
WO2023016551A1 (en) | Pyrrolo six-membered heteroaromatic compound for treating or preventing graft-versus-host disease | |
ES2965454T3 (en) | Improved protocol for the treatment of lupus nephritis | |
US11833155B2 (en) | Combination therapy for treatment of myeloproliferative neoplasms | |
WO2022268083A1 (en) | Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease | |
US7998973B2 (en) | Tivozanib and temsirolimus in combination | |
RU2322238C2 (en) | Treatment of proliferative arthritis | |
US20070287689A1 (en) | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | |
JP2024505194A (en) | Methods and compositions for inducing tolerance | |
JP2023529365A (en) | Combination of ruxolitinib and INCB057643 for the treatment of myeloproliferative neoplasms | |
CN112274511B (en) | Quinoline derivatives for the treatment of graft versus host disease | |
WO2021088975A1 (en) | Use of compound in preventing or treating graft versus host disease | |
JPH05310573A (en) | Therapeutic agent for rheumatism | |
US20230381179A1 (en) | Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | |
WO2024027790A1 (en) | Use of pyrrolopyrimidine compound in treatment of acute graft versus host disease | |
Ponticelli et al. | The pharmacology of old and new agents for specific therapy of primary glomerular diseases | |
WO2023194525A1 (en) | Combination therapy for treating cancer | |
Kaufman | Combining therapies with interferon beta for relapsing and early progressive MS: a review | |
US20230132982A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
WO2023194530A1 (en) | Combination therapy for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22855531 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |